Gerald Kleymann

Munich, BY, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Helicase-primase inhibitors as next-generation anti-HSV agents: from current clinical status to structure-activity relationships and patent coverage.

Helicase-primase inhibitors as next-generation anti-HSV agents: from current clinical status to structure-activity relationships and patent coverage.

Journal: Expert opinion on therapeutic patents

Published: July 27, 2026

Susceptibility of clinical isolates, laboratory-adapted and drug-resistant herpes simplex virus strains to helicase-primase inhibitor adibelivir (IM-250) and its synergy in combination therapy with acyclovir, penciclovir and foscarnet.

Susceptibility of clinical isolates, laboratory-adapted and drug-resistant herpes simplex virus strains to helicase-primase inhibitor adibelivir (IM-250) and its synergy in combination therapy with acyclovir, penciclovir and foscarnet.

Journal: Antiviral research

Published: June 09, 2026

A UPLC-MS/MS assay for the quantification of the novel viral helicase-primase drug candidate adibelivir (IM-250) in human specimen.

A UPLC-MS/MS assay for the quantification of the novel viral helicase-primase drug candidate adibelivir (IM-250) in human specimen.

Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Published: January 09, 2026

Evaluation of the patent portfolio for helicase-primase inhibitor ABI-5366 of Assembly Biosciences Inc.

Evaluation of the patent portfolio for helicase-primase inhibitor ABI-5366 of Assembly Biosciences Inc.

Journal: Expert opinion on therapeutic patents

Published: August 19, 2025

Structural determinants of nervous system exposure of adibelivir (IM-250) and related herpes helicase-primase inhibitors across animal species.

Structural determinants of nervous system exposure of adibelivir (IM-250) and related herpes helicase-primase inhibitors across animal species.

Journal: Antiviral research

Published: June 23, 2025

Identification of JNJ-61803534, a RORγt Inverse Agonist for the Treatment of Psoriasis.

Identification of JNJ-61803534, a RORγt Inverse Agonist for the Treatment of Psoriasis.

Journal: Journal of medicinal chemistry

Published: April 16, 2025

Meeting report of the 37th International Conference on Antiviral Research in Gold Coast, Australia, May 20-24, 2024, organized by the International Society for Antiviral Research.

Meeting report of the 37th International Conference on Antiviral Research in Gold Coast, Australia, May 20-24, 2024, organized by the International Society for Antiviral Research.

Journal: Antiviral research

Published: October 12, 2024

Helicase-primase inhibitors for the treatment of herpes simplex virus infections - patent evaluation of WO2023/225162 from Gilead Sciences Inc.

Helicase-primase inhibitors for the treatment of herpes simplex virus infections - patent evaluation of WO2023/225162 from Gilead Sciences Inc.

Journal: Expert opinion on therapeutic patents

Published: September 12, 2024

Replacement of sulfonamide by sulfoximine within a helicase-primase inhibitor with restricted flexibility.

Replacement of sulfonamide by sulfoximine within a helicase-primase inhibitor with restricted flexibility.

Journal: Bioorganic & medicinal chemistry letters

Published: January 31, 2024

Intermittent therapy with helicase-primase inhibitor IM-250 efficiently controls recurrent herpes disease and reduces reactivation of latent HSV.

Intermittent therapy with helicase-primase inhibitor IM-250 efficiently controls recurrent herpes disease and reduces reactivation of latent HSV.

Journal: Antiviral research

Published: August 25, 2023

Helicase-primase inhibitors from Medshine Discovery Inc. (WO2018/127207 and WO2020/007355) for the treatment of herpes simplex virus infections - structure proposal for Phaeno Therapeutics drug candidate HN0037.

Helicase-primase inhibitors from Medshine Discovery Inc. (WO2018/127207 and WO2020/007355) for the treatment of herpes simplex virus infections - structure proposal for Phaeno Therapeutics drug candidate HN0037.

Journal: Expert opinion on therapeutic patents

Published: August 15, 2022

Comprehensive clinical and virological characterization of three cases of fulminant liver failure owing to HSV1 primary infection.

Comprehensive clinical and virological characterization of three cases of fulminant liver failure owing to HSV1 primary infection.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: August 10, 2021

Showing 1-12 of 18

Last Updated: 09/26/2026